Literature DB >> 10535434

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

D K Shay1, R C Holman, R D Newman, L L Liu, J W Stout, L J Anderson.   

Abstract

CONTEXT: Respiratory syncytial virus (RSV) causes more lower respiratory tract infections, often manifested as bronchiolitis, among young children than any other pathogen. Few national estimates exist of the hospitalizations attributable to RSV, and recent advances in prophylaxis warrant an update of these estimates.
OBJECTIVES: To describe rates of bronchiolitis-associated hospitalizations and to estimate current hospitalizations associated with RSV infection. DESIGN AND
SETTING: Descriptive analysis of US National Hospital Discharge Survey data from 1980 through 1996. PARTICIPANTS: Children younger than 5 years who were hospitalized in short-stay, non-federal hospitals for bronchiolitis. MAIN OUTCOME MEASURE: Bronchiolitis-associated hospitalization rates by age and year.
RESULTS: During the 17-year study period, an estimated 1.65 million hospitalizations for bronchiolitis occurred among children younger than 5 years, accounting for 7.0 million inpatient days. Fifty-seven percent of these hospitalizations occurred among children younger than 6 months and 81 % among those younger than 1 year. Among children younger than 1 year, annual bronchiolitis hospitalization rates increased 2.4-fold, from 12.9 per 1000 in 1980 to 31.2 per 1000 in 1996. During 1988-1996, infant hospitalization rates for bronchiolitis increased significantly (P for trend <.001), while hospitalization rates for lower respiratory tract diseases excluding bronchiolitis did not vary significantly (P for trend = .20). The proportion of hospitalizations for lower respiratory tract illnesses among children younger than 1 year associated with bronchiolitis increased from 22.2% in 1980 to 47.4% in 1996; among total hospitalizations, this proportion increased from 5.4% to 16.4%. Averaging bronchiolitis hospitalizations during 1994-1996 and assuming that RSV was the etiologic agent in 50% to 80% of November through April hospitalizations, an estimated 51, 240 to 81, 985 annual bronchiolitis hospitalizations among children younger than 1 year were related to RSV infection.
CONCLUSIONS: During 1980-1996, rates of hospitalization of infants with bronchiolitis increased substantially, as did the proportion of total and lower respiratory tract hospitalizations associated with bronchiolitis. Annual bronchiolitis hospitalizations associated with RSV infection among infants may be greater than previous estimates for RSV bronchiolitis and pneumonia hospitalizations combined.

Entities:  

Mesh:

Year:  1999        PMID: 10535434     DOI: 10.1001/jama.282.15.1440

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  394 in total

1.  Lower respiratory tract infections among human immunodeficiency virus-exposed, uninfected infants.

Authors:  Marisa M Mussi-Pinhata; Fabrizio Motta; Laura Freimanis-Hance; Ricardo de Souza; Edgardo Szyld; Regina C M Succi; Celia D C Christie; Maria J Rolon; Mariana Ceriotto; Jennifer S Read
Journal:  Int J Infect Dis       Date:  2010-05-08       Impact factor: 3.623

2.  Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation.

Authors:  Lewis H McCurdy; Barney S Graham
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  When should nebulized hypertonic saline solution be used in the treatment of bronchiolitis?

Authors:  Jeffrey Hom; Ricardo M Fernandes
Journal:  Paediatr Child Health       Date:  2011-03       Impact factor: 2.253

4.  Viral detection using DNA functionalized gold filaments.

Authors:  Jonas W Perez; Frederick R Haselton; David W Wright
Journal:  Analyst       Date:  2009-05-15       Impact factor: 4.616

5.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

6.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  RSV604, a novel inhibitor of respiratory syncytial virus replication.

Authors:  Joanna Chapman; Elizabeth Abbott; Dagmar G Alber; Robert C Baxter; Sian K Bithell; Elisa A Henderson; Malcolm C Carter; Phil Chambers; Ann Chubb; G Stuart Cockerill; Peter L Collins; Verity C L Dowdell; Sally J Keegan; Richard D Kelsey; Michael J Lockyer; Cindy Luongo; Pilar Najarro; Raymond J Pickles; Mark Simmonds; Debbie Taylor; Stan Tyms; Lara J Wilson; Kenneth L Powell
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.

Authors:  Hajrija Maksić; Suada Heljić; Fahrija Skokić; Darinka Šumanović-Glamuzina; Veroslava Milošević; Almir Zlatanović; Notario Gerard
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

9.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 10.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.